LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy.
about
A systematic screen for micro-RNAs regulating the canonical Wnt pathwayMammary Development and Breast Cancer: A Wnt PerspectiveFrizzled7: A Promising Achilles' Heel for Targeting the Wnt Receptor Complex to Treat CancerDevelopment of anticancer agents targeting the Wnt/β-catenin signalingTargeting the Wnt pathways for therapiesFrizzled homolog proteins, microRNAs and Wnt signaling in cancerDuctal barriers in mammary epitheliumNiclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/β-catenin pathwayThe antihelmintic drug pyrvinium pamoate targets aggressive breast cancerWnt inhibitory factor 1 (WIF1) methylation and its association with clinical prognosis in patients with chondrosarcoma.The LRP6 rs2302685 polymorphism is associated with increased risk of myocardial infarction.Differentiation generates paracrine cell pairs that maintain basaloid mouse mammary tumors: proof of concept.Kallistatin antagonizes Wnt/β-catenin signaling and cancer cell motility via binding to low-density lipoprotein receptor-related protein 6Salinomycin suppresses LRP6 expression and inhibits both Wnt/β-catenin and mTORC1 signaling in breast and prostate cancer cellsThe embryonic transcription cofactor LBH is a direct target of the Wnt signaling pathway in epithelial development and in aggressive basal subtype breast cancersRepression of Wnt signaling by a Fer-type nonreceptor tyrosine kinase.Prescriptions of traditional Chinese medicine are specific to cancer types and adjustable to temperature changes.Upregulation of the Wnt co-receptor LRP6 promotes hepatocarcinogenesis and enhances cell invasionTyrosine-based signal mediates LRP6 receptor endocytosis and desensitization of Wnt/β-catenin pathway signaling.MiR-126-3p suppresses tumor metastasis and angiogenesis of hepatocellular carcinoma by targeting LRP6 and PIK3R2.Wnt and mammary stem cells: hormones cannot fly wingless.Deficiency in LRP6-mediated Wnt signaling contributes to synaptic abnormalities and amyloid pathology in Alzheimer's disease.FH535 inhibited migration and growth of breast cancer cells.Impact of Salinomycin on human cholangiocarcinoma: induction of apoptosis and impairment of tumor cell proliferation in vitroThe C-terminal region Mesd peptide mimics full-length Mesd and acts as an inhibitor of Wnt/β-catenin signaling in cancer cells.Key signaling nodes in mammary gland development and cancer: β-catenin.Downregulation of miR-610 promotes proliferation and tumorigenicity and activates Wnt/β-catenin signaling in human hepatocellular carcinoma.DEAD-box protein p68 is regulated by β-catenin/transcription factor 4 to maintain a positive feedback loop in control of breast cancer progressionMammary cells with active Wnt signaling resist ErbB2-induced tumorigenesisSyndecan-1 (CD138) modulates triple-negative breast cancer stem cell properties via regulation of LRP-6 and IL-6-mediated STAT3 signaling.Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells.Rad6B acts downstream of Wnt signaling to stabilize β-catenin: Implications for a novel Wnt/β-catenin target.Mesd is a general inhibitor of different Wnt ligands in Wnt/LRP signaling and inhibits PC-3 tumor growth in vivo.Transcriptome analysis of Wnt3a-treated triple-negative breast cancer cells.Activating the Wnt/β-Catenin Pathway for the Treatment of Melanoma--Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3Breast cancer growth and metastasis: interplay between cancer stem cells, embryonic signaling pathways and epithelial-to-mesenchymal transition.Both LRP5 and LRP6 receptors are required to respond to physiological Wnt ligands in mammary epithelial cells and fibroblasts.Silibinin inhibits Wnt/β-catenin signaling by suppressing Wnt co-receptor LRP6 expression in human prostate and breast cancer cells.Wnt signaling in mammary glands: plastic cell fates and combinatorial signaling.SOX9 regulates low density lipoprotein receptor-related protein 6 (LRP6) and T-cell factor 4 (TCF4) expression and Wnt/β-catenin activation in breast cancer.
P2860
Q21134995-DE19E424-AC75-4B88-A349-917724540DF4Q26740086-A0178723-EC9B-4D6B-B4A1-D283A66BA096Q26747651-8647E181-761D-49F1-B64F-EA78CCD453F9Q26781898-0F741326-DB40-4C91-A042-398B6E7CBD11Q26821978-F206D4DD-9906-49C2-BA0D-A3C3C97F9937Q27010132-DF7CC798-45B6-4FE7-A565-20DC6A0947B8Q27023960-79E37634-EB02-4DC8-A930-1E87A41020F9Q28478466-A26B1FDD-8D70-4D25-8CEA-2BAFEFE6282EQ28535721-75431D1C-47BF-4F41-9BE7-A4B8690DBAF1Q33685717-6D18F3A2-C539-4492-8D63-5D74BBE18480Q33761093-008882AE-A3D6-441A-8498-8557BB18BE30Q33889275-8A7C7150-85C9-46E3-B513-1ECCE2648D04Q33939375-C6E86D7E-3100-4154-B692-C45539329832Q34052780-D9FA3338-7B8C-478B-B239-4DEF508C8019Q34119756-8054CEC0-209D-4444-8BF7-079416A0BA66Q34136391-F0B81E61-FA9E-403F-B66C-7E60F1EC0509Q34168327-F937B0E5-0AD9-4371-AF5D-AD46F3B35F95Q34263359-1A5F1FC9-1837-4272-A25A-CF0086016F77Q34283427-C6FE4EBD-D9E2-4284-8157-382E98495473Q34306118-9DB23990-F56F-4EF4-9323-9ED7BF437CE7Q34311270-03884F67-0CEE-4047-9E7B-65B7C34DDEDFQ34350189-ED728F70-6861-4350-A090-50B7AC3E7502Q34415881-46D73926-A366-4654-92AE-D0FF8B4935F6Q34443640-74526B32-84BC-430F-A461-5FC7D8798F0CQ34612838-7BA67B27-7807-4268-8D29-20C1F9A0A878Q34613461-F2B8A764-F97A-4DEC-AE40-04D73E2EB825Q34967879-3A668962-15C9-4050-97FF-CE768A90C3D2Q35021360-5B40A44E-2EB1-499B-AA0A-E3BBE68874CFQ35050344-29D76C96-A603-4A34-B668-A010C90E2649Q35083176-5C06071D-105C-4592-952B-F981E5A13D4EQ35164584-4315BECF-A043-4601-B808-858CB642AAEBQ35179258-0A1CD425-86E5-46F4-B8F2-BEDE62475AAFQ35243349-2E18F501-CFB6-41BB-A669-F4445DE73BD7Q35300556-AD207224-6D01-4E4C-B3E6-B25444C6FE22Q35542572-F069D8BD-D022-414C-A75E-22CF31FC71EEQ35558027-F3D91338-1FAE-4316-9841-17162E144D0BQ35956457-18D7A405-7EC6-4EEC-BA91-08C0F5E61720Q36303639-0831D2E1-9896-48DA-9361-A27A3CF49CBEQ36329477-F8CD3534-3428-49A8-B5BF-9DBB3AC8DA8DQ36647355-2AC9138C-A599-4F0A-9D51-773A1CEE7AAA
P2860
LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy.
@ast
LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy.
@en
type
label
LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy.
@ast
LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy.
@en
prefLabel
LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy.
@ast
LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy.
@en
P2093
P2860
P356
P1476
LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy.
@en
P2093
Chia-Chen Liu
David Piwnica-Worms
Julie Prior
P2860
P304
P356
10.1073/PNAS.0911220107
P407
P577
2010-03-01T00:00:00Z